Background And Aims: One of the causes of preterm labor and recurrent abortion is progesterone deficiency in the luteal phase. The aim of the study was a comparison of the effect of oral dydrogesterone and vaginal progesterone for luteal-phase support (LPS) in assisted reproductive technology cycles (ART).
Methods: This randomized clinical control trial study was conducted on 207 infertile women. Samples were randomly divided into two groups. The first group received a natural micronized vaginal progesterone (MVP) of 400 mg once daily and the second group received dydrogesterone (Duphestone) 20 mg twice daily. Then chemical pregnancy, abortion, and live births were compared in two groups.
Results: The results of the study showed that the vaginal form of the drug could increase the chance of pregnancy (positive β-human chorionic gonadotropin) versus the oral form. According to the results of multiple logistic regression analysis after adjusting for other variables, the live birth rate in the vaginal group was more than five times that of the oral group (odds ratio = 5.07; 95% confidence interval = 1.24-20.65; = 0.023).
Conclusion: The vaginal form of the progesterone could increase the chance of pregnancy and the outcome of fertility (live birth). Thus, vaginal progesterone is effective for LPS in women undergoing fresh embryo transfer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11310270 | PMC |
| http://dx.doi.org/10.1002/hsr2.2296 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Carcinosarcoma of uterus in nulliparous women.
Front Oncol
December 2024
Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Article Synopsis
- Uterine carcinosarcoma (UCS) is a rare cancer combining both carcinoma and sarcoma features, often resembling endometrial carcinoma, with a potential link to nulliparity (never having given birth) as a risk factor.
- A 55-year-old woman presented with postmenopausal vaginal bleeding and was diagnosed after surgery, revealing well-differentiated adenocarcinoma and osteosarcoma components, along with multiple positive immunohistochemical markers.
- Following a series of surgical interventions and treatments, including chemotherapy and radiotherapy, the patient demonstrated no signs of tumor recurrence and had a disease-free survival of seven months as of July 2024.
Perinatal outcomes of progesterone in natural frozen-thawed embryo transfer pregnancies: insights from two randomized controlled trials.
Fertil Steril
December 2024
Department of Women's and Children's Health, Uppsala University, 751 85 Uppsala, Sweden; Reproduction Center, Uppsala University Hospital, 751 85 Uppsala, Sweden; Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Objective: To explore whether progesterone supplementation during luteal phase and early pregnancy following a natural frozen-thawed embryo transfer cycle (NC-FET) affects perinatal outcomes.
Design: A secondary data analysis study based on two randomized control trials taking place during 2008-2011 and 2013-2018 at two university hospitals in Sweden.
Subjects: A total of 923 women undergoing a natural FET cycle.
A 12-h Difference in Exogenous Progesterone Initiation Does Not Have an Impact on Ongoing Pregnancy Rates in Artificial Cycles, as Long as Luteal Phase Support Starts Five Days Before Blastocyst Transfer.
Reprod Sci
December 2024
Global Research Alliance - IVI Foundation (IIS La Fe). Research Department, Avinguda de Fernando Abril Martorell, 106. 46026, Valencia, Spain.
Purpose: To elucidate if morning or evening start of exogenous progesterone (P4) five days before blastocyst embryo transfer (ET) impacts ongoing pregnancy rates (OPR) in artificial cycles.
Methods: Single-centre retrospective cohort study of 6493 artificial cycles for an ET (oestrogens and luteal phase support [LPS] with micronized vaginal progesterone [MVP] 400 mg/12 h), conducted at an infertility clinic, December 2018-July 2022. LPS was given from five days before ET.
Evaluation of two luteal support regimens, intramuscular progesterone and progesterone vaginal gel, for vitrified-warmed embryo transfer in women with chronic salpingitis: a single-center 8-year retrospective study.
Eur J Med Res
December 2024
Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Background: Chronic salpingitis is one of the most common causes of female infertility. Luteal support is a critical step for embryo transfer. Here, we evaluated the effects of two luteal support regimens, intramuscular progesterone (IMP) and progesterone vaginal gel (VAG), on the pregnancy outcomes in patients with chronic salpingitis undergoing vitrified-warmed embryo transfer.
View Article and Find Full Text PDFOral dydrogesterone along with vaginal micronized progesterone supplementation for luteal phase support in IVF patients, and its impact on pregnancy and live birth rates: a prospective randomized trial.
BMC Pregnancy Childbirth
December 2024
One Day Medical Center, Via Attilio Ambrosini 114, Rome, 00147, Italy.
Background: A normal luteal function is an essential factor for maintaining pregnancy; luteal phase deficiency decreases embryo implantation and pregnancy rate and increases the early miscarriage rate. In stimulated in vitro fertilization-embryo transfer (IVF-ET) patients, luteal phase support (LPS) is achieved by the exogenous supplementation with progesterone to increase endometrial receptivity and pregnancy. While several protocols exist, no commonly accepted protocol has been established for optimal luteal support after IVF-ET to date, the purpose of this study was to investigate the effect of two different luteal phase support protocols in patients undergoing assisted reproductive technologies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!